Pharmafile Logo
Pharmafocus logo
Advanced Search

Yervoy

Showing 15 posts of 56 posts found.

fda2outsideweb

Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma

October 6, 2020
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo

Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …

News
4353113087_4d19c3a402_b

Bristol-Myers Squibb demonstrates potential for long-term survival in kidney cancer patients treated with Opdivo plus Yervoy

February 20, 2020
Business Services Cancer, Cancers, Yervoy, opdivo, renacl cell carcinoma, renal cancer

Bristol-Myers Squibb has announced updated results from trialing Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated …

News
humacao_exterior

BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer

February 3, 2020
Sales and Marketing BMS, Cancer, Europe, Yervoy, lung cancer, opdivo

Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and …

News
opdivo_1_1

BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer

October 23, 2019
Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …

News

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

April 5, 2019
Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …

News

Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application

January 25, 2019
Medical Communications BMS, Merck, Yervoy, ctla4, lung cancer, opdivo

Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer. …

News
bmssyracuseny

BMS’ Opdivo+Yervoy combo fails in small cell lung cancer

November 27, 2018
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …

News

BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

October 22, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …

News

BMS’ Opdivo+Yervoy combo secures FDA approval in kidney cancer

April 18, 2018
Research and Development, Sales and Marketing BMS, Bristol Myers Swuibb, Cancer, FDA, Yervoy, carcinoma, opdivo, pharma

The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …

News

BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

February 6, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …

News

Bristol-Myers Squibb’s Yervoy scores EU approval in paediatric melanoma

January 23, 2018
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, EU, Yervoy, pharma

Bristol-Myers Squibb has revealed that its immunotherapy Yervoy (ipilimumab) has received an expanded indication from the European Commission, approving the …

News
opdivo_1_1

BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer

August 16, 2017
Research and Development BMS, Kidney cancer, Yervoy, life sciences, opdivo, pharma, pharmaceutical

Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …

News
shutterstock_291014192

Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

March 21, 2017
Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …

News

BMS shares promising Opdivo/Yervoy data for advanced bladder cancer

December 8, 2016
Research and Development BMS, Yervoy, opdivo

BMS has revealed new efficacy data on the combination of its immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment …

News
humacao_exterior

BMS unveils reorganisation plans & boosted profits

October 28, 2016
Business Services, Medical Communications Bristol-Myers Squibb, Yervoy, opdivo

BMS has announced its intention to restructure its operations alongside $3 billion share buyback and quarterly results which exceeded expectations.The …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024